For Cai Lei, the former JD.com executive turned ALS crusader, the battle against amyotrophic lateral sclerosis has moved from personal survival to industrial disruption. Marking his seventh 'Father’s Day' since diagnosis, Cai has shifted his focus toward the financial 'suffocation' of his peers, specifically the prohibitive cost of life-sustaining ventilators. While imported machines can cost nearly a year's salary for average Chinese workers, Cai's partnership with Haier aimed to break the market with a device priced 80% lower than foreign alternatives.
Despite the significant price reduction and a 'Consumer-to-Manufacturer' (C2M) approach, the initiative has encountered an unexpected hurdle: the skepticism of the very patients it intended to save. Out of an anticipated demand for thousands, only about 500 units have been sold, with many patients opting to stay with aging, high-priced imports or risky second-hand equipment. This 'cold reception' highlights the deep-seated trust gap and the complex psychology of medical consumption in China’s high-stakes healthcare environment.
The technical requirements for ALS patients are grueling; unlike sleep apnea patients who use ventilators for eight hours a night, ALS patients often require 24/7 support. This puts immense pressure on component longevity and software algorithms, areas where established foreign brands like ResMed have built decades of brand equity. Many Chinese families, fearing that 'cheap means low quality,' are hesitant to trust a domestic newcomer with a life-critical function, even when backed by a household name like Haier.
Beyond brand perception, the struggle reflects the fragmented and often predatory nature of medical device distribution in China. Middlemen and existing distributors of foreign brands have allegedly fueled rumors to protect their margins, warning patients that the subsidized Haier units are unreliable. For Cai, this resistance is a 'shameful' setback that risks sending a negative signal to other tech giants who might otherwise consider investing in the low-margin, high-risk 'orphan' market of rare diseases.
Haier’s involvement, driven by Chairman Zhou Yunjie, represents a rare philanthropic foray by a major Chinese industrialist into the 'medical-social' space. The company customized the hardware and software specifically for the respiratory patterns of ALS patients, even providing specialized heating tubes for environmental variances. However, the high cost of personalized after-sales service and the need for constant parameter adjustments mean that even at a lower price point, the business model remains fragile without scale.
Ultimately, Cai Lei’s experiment serves as a litmus test for the 'warrior' ethos he champions among the rare disease community. He argues that patients must move from being passive recipients of charity to active participants in creating their own technology ecosystems. If domestic innovators cannot find a foothold in these specialized niches due to community skepticism, the dependency on expensive foreign medical technology will continue to leave China’s most vulnerable families behind.